Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- SANTA MONICA, Calif. – April 2, 2026 – The U.S. Food and Drug Administration (FDA) has granted traditional (full) approval to Kite’s CAR T-cell therapy, Tecartus (brexucabtagene autoleucel), for adult patients with relapsed or…
- TARRYTOWN, N.Y., April 02, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of dosing intervals for Eylea HD® (aflibercept) up to…
- INDIANAPOLIS, April 1, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical…
- BOSTON–(BUSINESS WIRE)–Apr. 1, 2026– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of…
- TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Ponlimsi…
- CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose Regimen of Spinraza (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug…
- MONDAY, April 13, 2026 — Survivors of nearly all types of adolescent and young adult cancer have an increased risk for developing a subsequent primary neoplasm, according to a study published online April 13 in CMAJ, the journal of the Canadian…
- MONDAY, April 13, 2026 — Apolipoprotein B (apoB) can be used as a cost-effective marker to guide primary prevention lipid-lowering therapy (LLT) compared with low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol…
- MONDAY, April 13, 2026 — Early-onset oral cavity squamous cell carcinoma (EO-OCSCC) is increasingly presenting as tongue tumors, and cases in women are increasing, according to a study published online Jan. 31 in Otolaryngology-Head and Neck…
- MONDAY, April 13, 2026 — A blood test for circulating tumor human papillomavirus DNA (ctHPVDNA) may improve risk assessment in patients undergoing surgery for HPV-related oropharyngeal cancer, according to a study published online April 2 in JAMA…
- MONDAY, April 13, 2026 — Individuals with long COVID have an increased risk for developing cardiovascular disease, according to a study published online April 1 in eClinicalMedicine. Pia Lindberg, from the Karolinska Institutet in Stockholm, and…
- MONDAY, April 13, 2026 — For patients with stage II to III colorectal cancer, duloxetine is no better than placebo for preventing sensory oxaliplatin-induced peripheral neuropathy (OIPN), according to a study published online March 25 in JCO…
Thông tin từ The Pharma Letter
- US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading.
- Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated.
- The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs.
- Lotte Bjerre Knudsen, chief scientific advisor to the chief scientific officer, vice president of innovation and data experimentation advancement (IDEA) at Danish pharma major Novo Nordisk, is to leave the company after 36 years.
- UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen.
- A new national project will develop a common information structure for clinical trials in Sweden.
Thông tin từ BioPharmaDive
- The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” profile, the company said.
- Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.
- The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor.
- A smarter approach to dermatology trials—built for durability and real-world impact.
- Connected medical devices are transforming healthcare and clinical trials, driving advances in patient care and next-gen therapies shaping the future.
- In a statement late Friday, CEO Sushil Patel disputed the FDA’s criticisms of the company and said Replimune had received “inconsistent communications.” It’ll be forced to cut jobs as well.
Thông tin từ STAT News
- The board will now oversee a process to lower the cost of the type 2 diabetes medicine Jardiance by January 2027.
- FDA officials said an internal analysis found results were not submitted for nearly 30% of studies “highly likely” to fall under mandatory reporting requirements.
- HaloMD is a middleman that became the top filer of out-of-network billing disputes on behalf of medical providers.
- CMS greenlights more than 150 digital health companies for its ACCESS experiment, a new program for tech-backed chronic care with outcome-aligned payments.
- President Trump vowed to take on health insurers, but his policies tell a different story.
- Revolution Medicines 'unprecedented' cancer trial data, Allogene's off-the-shelf CAR-T, and other biotech news
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 10 April 2026; doi:10.1038/d41573-026-00056-yBioconjugated oligonucleotides (BCOs) promise to expand the applicability of RNA-based medicines. Here, we present recommendations for nonclinical safety strategies in advancing BCOs into the clinic.
- Nature Reviews Drug Discovery, Published online: 07 April 2026; doi:10.1038/d41573-026-00058-wLipid nanoparticles deliver to the pancreas
- Nature Reviews Drug Discovery, Published online: 02 April 2026; doi:10.1038/d41573-026-00057-xDialling up the circadian clock to target ageing
- Nature Reviews Drug Discovery, Published online: 02 April 2026; doi:10.1038/s41573-026-01407-5The oral delivery of small-molecule drugs with poor aqueous solubility represents an ongoing drug development challenge. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) have emerged as effective approaches to address this. This Perspective provides an overview of the design of ASDs and LBFs and examines […]
- Nature Reviews Drug Discovery, Published online: 02 April 2026; doi:10.1038/d41573-026-00059-9FDA approves GLP-1 pill for obesity
- Nature Reviews Drug Discovery, Published online: 30 March 2026; doi:10.1038/s41573-026-01388-5The PI3K/AKT/mTOR pathway represents an attractive drug target, but only a limited number of compounds have gained US Food and Drug Administration approval. This Perspective assesses existing class I PI3K/AKT/mTOR pathway inhibitors, highlighting lessons learned and ongoing drug development challenges. Emerging novel classes of pathway modulators, […]